Hypotonic(Floppy) Infant: Clinical Case Discussion & Viva Key Points
Model Case Presentation
Patient Demographics
Name: Baby Arjun, Age: 3 months, Gender: Male, Informant: Mother (Reliable)
Chief Complaints
- Limpness / decreased movements since birth
- Difficulty in feeding and weak cry since birth
- Poor head control – 3 months
History Summary
Mother noticed the baby was unusually "limp" from birth. He has never held his head up, does not kick his legs vigorously, and limbs droop when lifted. Feeding is poor — weak suck, tires quickly, frequent choking. Cry is weak and high-pitched. No rolling or purposeful limb movements. No seizures. Siblings are normal. Consanguineous marriage (first cousins). Mother recalls reduced fetal movements in the last trimester. Born at term via normal vaginal delivery; no birth asphyxia. No maternal illness during pregnancy. Neonatal period: required brief NICU stay for feeding difficulties.
Baby is alert, makes good eye contact, tracks objects visually, and smiles — indicating preserved cognition.
Examination Summary
| Parameter | Finding | Significance |
|---|---|---|
| Weight | 4.1 kg | Failure to thrive (expected ~6 kg) |
| Cry | Weak, high-pitched | Bulbar/muscle weakness |
| Alertness | Alert, good eye contact | Cognition preserved — suggests peripheral cause |
| Resting posture | Frog-leg posture | Profound hypotonia |
| Traction response | Complete head lag | Severe axial hypotonia |
| Ventral suspension | Inverted "U" / drapes over hand | Generalized hypotonia |
| Vertical suspension | Slips through hands | Shoulder girdle weakness |
| Deep tendon reflexes | Absent (areflexia) | Lower motor neuron / anterior horn cell |
| Muscle bulk | Reduced (proximal > distal) | Neurogenic atrophy |
| Tongue | Fasciculations present | Anterior horn cell disease — SMA |
| Chest | Bell-shaped chest, paradoxical breathing | Weak intercostals, preserved diaphragm |
| Facial expressions | Normal | Facial muscles spared |
| Sensation | Intact | Pure motor disorder |
✅ Complete Diagnosis
Floppy Infant — Peripheral Hypotonia due to Spinal Muscular Atrophy Type I (Werdnig–Hoffmann Disease) with Failure to Thrive and Impending Respiratory Failure.
Why SMA Type I?
- Onset before 6 months, consanguineous parents (autosomal recessive)
- Alert baby with profound flaccid weakness — classic peripheral pattern
- Tongue fasciculations — pathognomonic of anterior horn cell disease
- Absent DTRs, proximal > distal weakness, bell-shaped chest
- Preserved sensation and cognition
📝 History — Exam Q&A
A floppy infant is one who demonstrates abnormal limpness — reduced resistance to passive movement, poor postural control, and inability to sustain movement against gravity. Clinically, these infants exhibit a "rag doll" appearance.
Hypotonia is defined as a subjective decrease in resistance to passive range of movement of joints. It is distinct from weakness (which is reduction in maximum muscle power generated). An infant can be hypotonic without being weak (e.g., Down syndrome) or weak without significant hypotonia (rare).
Central hypotonia (CNS origin) is by far the most common, accounting for 60–80% of all cases of infantile hypotonia. The most common central cause is hypoxic-ischemic encephalopathy (HIE).
Peripheral hypotonia (lower motor neuron, NMJ, or muscle) accounts for 15–30% of cases. The most common peripheral causes are congenital myopathies, SMA, and congenital myotonic dystrophy.
I. Central (Upper Motor Neuron) — 60–80%
| Category | Examples |
|---|---|
| Hypoxic-Ischemic | HIE, birth asphyxia |
| Chromosomal / Genetic | Down syndrome (Trisomy 21), Prader-Willi syndrome (del 15q11-13), Trisomy 13, 18 |
| Structural brain | Lissencephaly, holoprosencephaly, cerebellar hypoplasia |
| Metabolic / IEM | Pompe disease (acid maltase deficiency), hypothyroidism, Zellweger syndrome, organic acidemias |
| Infection | TORCH infections, sepsis, meningitis |
II. Peripheral (Lower Motor Neuron) — 15–30%
| Level | Examples |
|---|---|
| Anterior Horn Cell | Spinal Muscular Atrophy (SMA) Types I, II |
| Peripheral Nerve | Congenital hypomyelinating neuropathy, Charcot-Marie-Tooth |
| Neuromuscular Junction | Neonatal myasthenia gravis, congenital myasthenic syndromes, infant botulism, hypermagnesemia |
| Muscle | Congenital myopathies (central core, nemaline), congenital muscular dystrophy, myotonic dystrophy |
💡 Memory Aid
"C-A-P-M" for peripheral levels: Cord (anterior horn), Axon (peripheral nerve), Plate (NMJ), Muscle.
| History Point | Significance |
|---|---|
| Reduced fetal movements in utero | Suggests hypotonia/weakness began prenatally (congenital myopathy, SMA, chromosomal) |
| Breech presentation | Associated with neuromuscular weakness in utero |
| Perinatal asphyxia / birth difficulty | Suggests HIE (central cause) |
| Normal at birth then deterioration | Metabolic disorder (IEM), sepsis, infant botulism |
| Consanguinity / family history | Autosomal recessive conditions (SMA, congenital myopathy) |
| Mother's symptoms (myotonia, ptosis) | Congenital myotonic dystrophy (maternally inherited) |
| Maternal MG / pyridostigmine use | Neonatal (transient) myasthenia gravis |
| Feeding honey or exposure to soil | Infant botulism |
| Constipation before hypotonia | Infant botulism (constipation is earliest sign) |
| Dysmorphic features query | Down syndrome, Prader-Willi |
Prader-Willi syndrome (deletion of paternal chromosome 15q11–q13) presents in two phases:
- Infancy: Severe hypotonia, feeding difficulty (tube feeding often required), hypogonadism (micropenis / cryptorchidism in males), almond-shaped eyes, narrow bifrontal diameter, downturned mouth
- Childhood onwards: Hyperphagia and insatiable appetite (risk of morbid obesity), short stature, cognitive impairment, behavioral problems
💡 Pearl
In infancy, Prader-Willi may be mistaken for SMA due to severe hypotonia. Key differentiators: PWS has dysmorphic features, hypogonadism, and normal tongue — no fasciculations.
Down syndrome is the most common chromosomal cause of a floppy infant. Hypotonia is universal and due to central (cortical) origin. Features include:
- Hypotonia with preserved alertness and social responsiveness
- Upslanting palpebral fissures, epicanthal folds, flat nasal bridge
- Single palmar crease (simian crease), sandal gap (1st/2nd toe), clinodactyly
- Protruding tongue, small ears, excessive posterior nuchal skin
- Brushfield spots in iris
- Associated CHD (40–50%), duodenal atresia, hypothyroidism
| Type | Eponym | Age of Onset | Max Motor Function | Prognosis |
|---|---|---|---|---|
| SMA I | Werdnig–Hoffmann | < 6 months | Never sits unaided | Death <2 yrs (without treatment) |
| SMA II | Dubowitz disease | 6–18 months | Sits, never walks | Reduced lifespan |
| SMA III | Kugelberg–Welander | > 18 months | Walks, may lose later | Near-normal lifespan |
| SMA IV | Adult-onset SMA | > 10 years | Walks | Normal lifespan |
All types are caused by homozygous deletion/mutation of SMN1 gene on chromosome 5q13, autosomal recessive. Severity inversely correlates with number of SMN2 gene copies.
Infant botulism occurs when Clostridium botulinum spores (ingested via honey or soil exposure) germinate in the gut and produce toxin, which blocks acetylcholine release at the NMJ.
Classic triad:
- Constipation — earliest and most consistent symptom (often precedes weakness by days)
- Descending flaccid paralysis — begins with cranial nerve involvement (ptosis, poor feeding, weak cry, loss of head control) then descends
- Alert infant — consciousness preserved, but profoundly weak
Affects infants < 6 months (peak 2–4 months). Diagnosis: stool culture for C. botulinum / toxin assay.
| Feature | Neonatal (Transient) MG | Congenital Myasthenic Syndrome (CMS) |
|---|---|---|
| Mechanism | Passive transfer of maternal AChR antibodies across placenta | Genetic mutation in NMJ proteins (not antibody-mediated) |
| Mother | Mother has MG | Mother unaffected |
| Onset | Birth to 72 hours | Birth or early infancy |
| Duration | Transient — resolves in 2–8 weeks as maternal antibodies clear | Persistent (lifelong) |
| Features | Weak cry, poor suck, hypotonia, ptosis, respiratory distress | Same + fatigability |
| Treatment | Supportive ± neostigmine; resolves spontaneously | Pyridostigmine (lifelong) |
Congenital myotonic dystrophy (CTD) is caused by a CTG trinucleotide repeat expansion in the DMPK gene on chromosome 19q. It is almost always inherited from the mother (maternal transmission) due to anticipation.
Infant features: Severe hypotonia from birth, facial diplegia (inverted "V" upper lip / tent-shaped mouth), feeding difficulty, respiratory failure, talipes. Cognitive impairment is common.
Why examine the mother? The mother may have subclinical or mild myotonic dystrophy (delayed relaxation of grip, grip myotonia, ptosis, cataracts). Examining her can reveal the diagnosis without invasive testing in the baby. She may not be aware of her diagnosis.
🩺 Examination — Exam Q&A
| Test | How to Do | Normal | Hypotonic |
|---|---|---|---|
| Traction (Pull-to-sit) | Pull infant from supine by the arms to sitting | Head maintained in line with trunk by 4 months | Complete head lag — head falls back |
| Ventral (Horizontal) suspension | Hold prone, palm under chest | Head up, back straight, limbs slightly flexed | Inverted "U" / drapes over hand like a rag doll |
| Vertical suspension | Hold upright under axillae | Infant grips examiner's hands with shoulders | "Slips through" the hands due to shoulder girdle weakness |
| Resting posture (supine) | Observe at rest | Slightly flexed limbs, symmetrical | Frog-leg posture — hips abducted, externally rotated, knees flexed flat |
| Passive range of movement | Move limbs through range | Normal resistance | Decreased resistance, hyperextensible joints |
| Scarf sign | Pull arm across chest toward opposite shoulder | Elbow does not cross midline | Elbow crosses midline easily |
The level of alertness / consciousness combined with deep tendon reflexes is the most critical differentiator:
| Feature | Central Hypotonia | Peripheral Hypotonia |
|---|---|---|
| Alertness / Consciousness | Reduced, lethargic, or encephalopathic | Alert, bright eyes, good social responsiveness |
| Weakness | Hypotonic but not profoundly weak | Profound weakness accompanying hypotonia |
| Deep Tendon Reflexes | Normal or hyperactive (may be reduced acutely) | Reduced or absent (areflexia) |
| Fasciculations | Absent | Present (especially tongue) in anterior horn cell disease |
| Seizures | May be present | Absent |
| Dysmorphic features | Often present (chromosomal) | Usually absent |
| Sensation | Intact | May be impaired (peripheral neuropathy) or intact (SMA) |
| Tongue | Normal | Fasciculations in SMA; myotonia in CMD |
💡 Key Rule of Thumb
"Alert and floppy = Peripheral. Encephalopathic and floppy = Central."
- Alert infant with expressive gaze (cognition completely spared)
- Profound, symmetrical flaccid weakness — proximal > distal, lower limbs > upper limbs
- Tongue fasciculations — pathognomonic; best seen with baby calm/sleeping
- Absent deep tendon reflexes (areflexia)
- Bell-shaped chest (intercostal muscles weak; diaphragm relatively spared)
- Paradoxical breathing — chest moves in while abdomen moves out on inspiration
- Frog-leg posture at rest
- Complete head lag on traction; drapes on ventral suspension
- No fasciculations in facial muscles — face is relatively spared
- Sensation: intact (pure motor disorder)
Normally, during inspiration, both the diaphragm and intercostal muscles contract, expanding the chest wall in all directions. In SMA, the intercostal muscles are predominantly weak, but the diaphragm is relatively spared. When the diaphragm contracts, it generates negative intrathoracic pressure, but the weak chest wall is sucked inward instead of expanding outward. This creates a paradoxical pattern: abdomen rises while chest wall retracts on inspiration — the "see-saw" or "abdominal" breathing pattern. It indicates significant respiratory muscle weakness and impending respiratory failure.
| Feature | SMA Type I | Congenital Myopathy |
|---|---|---|
| Tongue fasciculations | Present | Absent |
| DTRs | Absent | Reduced or absent |
| Facial weakness | Mild / spared | Often prominent (facial diplegia) |
| Ptosis / ophthalmoplegia | Absent | May be present (centronuclear myopathy) |
| Serum CK | Normal or mildly elevated | Normal to markedly elevated (depending on type) |
| EMG | Neurogenic pattern (fibrillations, sharp waves, polyphasic MUPs, decreased recruitment) | Myopathic pattern (small, short MUPs, early recruitment) |
| Muscle biopsy | Group atrophy (neurogenic) | Structural changes (cores, nemaline rods, etc.) |
| Gene | SMN1 deletion (5q13) | Specific gene (RYR1 for central core, NEB for nemaline, etc.) |
- Hypotonia: Central, generalized, associated with joint hypermobility
- Facial: Upslanting palpebral fissures, epicanthal folds, flat nasal bridge, small ears, protruding tongue, Brushfield spots in iris
- Head: Brachycephaly (flat occiput), small head
- Hands: Simian crease (single palmar crease), short 5th finger with clinodactyly, brachydactyly
- Feet: Sandal gap (wide space between 1st and 2nd toes)
- Neck: Short, excess posterior nuchal skin
- DTRs: Normal or reduced (central hypotonia — no fasciculations)
- Associated: CHD (40–50%); duodenal atresia (double bubble), hypothyroidism, atlantoaxial instability
Pompe disease (autosomal recessive; GAA gene mutation) is unique as it causes both central and peripheral hypotonia. Classic infantile Pompe presents as:
- Severe generalized hypotonia — "floppy infant" from birth
- Cardiomegaly / hypertrophic cardiomyopathy — hallmark; may cause cardiac failure
- Macroglossia (large tongue)
- Hepatomegaly
- ECG: Short PR interval, tall QRS complexes
- Serum CK: markedly elevated
🚨 Remember
In a floppy infant with cardiomegaly + macroglossia, always think Pompe disease. Enzyme replacement therapy (alglucosidase alfa) is available and time-critical.
🔬 Investigations — Exam Q&A
Step 1 — Establish stability: ABCs, SpO₂, glucose, sepsis screen (FBC, CRP, blood culture) in every sick hypotonic neonate.
Step 2 — Localize (Central vs Peripheral): Clinical history and neurological examination.
If Central suspected:
- MRI brain (structural/metabolic abnormalities)
- Karyotype / chromosomal microarray (Down, Prader-Willi)
- FISH/methylation studies (15q11 for PWS)
- Metabolic screen (blood glucose, ammonia, lactate, amino acids, organic acids, TFTs)
- TORCH screen, EEG if seizures
If Peripheral suspected:
- Serum CK (elevated in myopathy; normal/mild elevation in SMA)
- EMG / Nerve Conduction Studies (NCS) — neurogenic vs myopathic pattern
- Genetic testing: SMN1 deletion (SMA) — first line if anterior horn cell suspected
- Muscle biopsy — for myopathies and muscular dystrophies
- Repetitive nerve stimulation — for NMJ disorders
- Stool culture / toxin assay — for botulism
- AChR antibodies in mother — neonatal MG
Genetic testing for SMN1 gene deletion is the gold standard for diagnosing SMA. Specifically, demonstration of homozygous deletion of exons 7 and 8 of SMN1 gene (chromosome 5q13) by MLPA (Multiplex Ligation-dependent Probe Amplification) or PCR-based testing.
- Sensitivity: >95% for all 5q-SMA types
- SMN2 copy number testing is additionally performed — higher copies = milder phenotype
- EMG and muscle biopsy are NOT required when clinical presentation is typical and genetic testing confirms the diagnosis
| Feature | SMA (Neurogenic) | Congenital Myopathy |
|---|---|---|
| Spontaneous activity | Fibrillations, positive sharp waves, fasciculation potentials | Usually absent (some exceptions) |
| Motor unit potentials (MUPs) | Large amplitude, long duration, polyphasic (giant MUPs) | Small amplitude, short duration (myopathic MUPs) |
| Recruitment | Reduced (few MUPs firing rapidly) | Early / full recruitment (many MUPs for little force) |
| NCS — sensory | Normal | Normal |
| NCS — motor | Normal velocity; reduced amplitude (CMAPs) | Normal or mildly reduced |
MRI brain is the primary investigation when central hypotonia is suspected. It helps identify:
- HIE: T1 shortening in basal ganglia / thalami; diffusion restriction in acute phase
- Brain malformations: Lissencephaly, polymicrogyria, holoprosencephaly, Joubert syndrome (molar tooth sign)
- Periventricular leukomalacia (PVL): In preterm infants
- Metabolic leukodystrophies: White matter changes in Zellweger, Krabbe, Canavan disease
- Cerebellar hypoplasia: In pontocerebellar hypoplasia
MR spectroscopy can additionally detect metabolite abnormalities (elevated lactate in mitochondrial disorders).
| SMA (Neurogenic atrophy) | Congenital Myopathy | |
|---|---|---|
| Pattern | Group atrophy — large groups of small, atrophic type I and II fibers, interspersed with groups of hypertrophic type I fibers | Structural myopathic changes (type-specific) |
| Central Core disease | — | Central areas devoid of mitochondria/oxidative enzymes on modified Gomori trichrome |
| Nemaline myopathy | — | Nemaline rods on modified Gomori trichrome (electron microscopy confirms) |
| Centronuclear myopathy | — | Centrally placed nuclei in muscle fibers |
| Inflammation | Absent | Absent (unless inflammatory myopathy) |
Note: Muscle biopsy for SMA is rarely needed now — genetic testing has replaced it in typical cases.
| Syndrome | Confirmatory Investigation | Finding |
|---|---|---|
| Down syndrome | Karyotype / chromosomal microarray | Trisomy 21 (47,XX or XY,+21); 3–5% are Robertsonian translocations |
| Prader-Willi syndrome | Methylation-specific PCR / FISH / chromosomal microarray | Deletion of paternal 15q11-q13 (70%), maternal UPD (25%), imprinting centre defect (5%) |
| CK Level | Likely Diagnosis |
|---|---|
| Normal or mildly elevated (< 500 U/L) | SMA, congenital neuropathy, central hypotonia |
| Moderately elevated (500–10,000 U/L) | Congenital myopathies (e.g., central core, nemaline), Pompe disease |
| Markedly elevated (>10,000 U/L or >10× ULN) | Congenital muscular dystrophy (especially merosin-deficient CMD), Duchenne (older), myositis |
💡 Pearl
In SMA, CK is characteristically normal or only mildly elevated, helping differentiate it from muscular dystrophies. Markedly elevated CK strongly points toward a primary muscle disease.
💊 Management — Exam Q&A
- Stabilize: Airway, breathing, circulation — hypotonic infants are at high risk of respiratory failure and aspiration
- Establish cause: Stepwise investigation as per clinical localization
- Nutritional support: Nasogastric / orogastric tube if feeding is insufficient; high-calorie formula; consider gastrostomy for long-term cases
- Respiratory support: Non-invasive ventilation (BiPAP/CPAP), cough assist devices, chest physiotherapy; mechanical ventilation if needed
- Physiotherapy: Prevent contractures, splinting, passive range of motion exercises
- Occupational therapy: Developmental support, adaptive devices
- Speech therapy: Feeding assessment, swallowing therapy
- Treat specific cause where available (see below)
- Genetic counseling: Recurrence risk for autosomal recessive conditions
- Palliative care: In severe cases (e.g., untreated SMA I) — discuss with family
Disease-modifying therapies (DMTs) — now available and effective:
| Drug | Mechanism | Route | Notes |
|---|---|---|---|
| Nusinersen (Spinraza) | Antisense oligonucleotide — modifies SMN2 splicing to produce more full-length SMN protein | Intrathecal (lumbar puncture) | FDA approved 2016; given at 0, 14, 28, 63 days then every 4 months |
| Onasemnogene abeparvovec (Zolgensma) | AAV9-based gene therapy — delivers functional SMN1 gene | IV single dose | FDA approved 2019; most effective if given pre-symptomatically or early; approved up to 2 years of age |
| Risdiplam (Evrysdi) | Small molecule — splicing modifier of SMN2 (similar to nusinersen) | Oral (syrup) | FDA approved 2020; advantage — oral administration |
Supportive care:
- Non-invasive ventilation (NIV) — BiPAP, especially at night
- Cough-assist devices (mechanical insufflation-exsufflation)
- Gastrostomy for nutrition
- Chest physiotherapy
- Scoliosis monitoring and management
No cure; management is multidisciplinary and supportive:
- Cardiac: Echo at birth; surgical correction of CHD if indicated
- Thyroid: TFTs at birth, 6 months, 12 months, then annually (hypothyroidism common)
- Vision: Ophthalmology referral (cataracts, refractive errors)
- Hearing: Audiological assessment (conductive hearing loss)
- Physiotherapy: For hypotonia, motor delay
- Atlantoaxial instability: Lateral X-ray of cervical spine; avoid activities with risk of neck injury
- Early intervention: Special education, speech therapy, behavioral support
- Genetic counseling: Recurrence risk (1% + maternal age risk for trisomy 21; ~10% if translocation)
- Leukemia surveillance: High risk for ALL and AML
- Hospitalization: ICU for monitoring of respiratory function
- Heptavalent Botulinum Antitoxin (HBAT): Available for types A, B, C, D, E, F, G — NOT recommended for infant botulism (antitoxin is equine-derived and not licensed for infants)
- BabyBIG (BIG-IV — Human botulism immune globulin IV): Specifically approved for infant botulism types A and B — neutralizes circulating toxin; dramatically reduces hospital stay and duration of illness. Administered as a single IV dose as early as possible
- Supportive care: Respiratory support (ventilation if needed), nutritional support (NG tube), bowel management
- Do NOT use: Antibiotics (metronidazole, aminoglycosides) — aminoglycosides potentiate NMJ blockade
- Do NOT use: Anticholinesterases (neostigmine) — not effective in botulism
Prognosis: Excellent with supportive care. Recovery is slow (weeks to months) as new NMJ sprouts form.
- Usually self-limiting — resolves within 2–8 weeks as maternal antibodies are cleared
- Neostigmine: Anticholinesterase — given for symptomatic control (feeding difficulty, respiratory distress); dose titrated to response
- Pyridostigmine: Oral anticholinesterase; longer acting; used for milder cases
- Respiratory support: If respiratory failure develops
- NG tube feeding: If sucking/swallowing are inadequate
- No need for immunosuppression — condition is transient
- Enzyme Replacement Therapy (ERT): Alglucosidase alfa (Myozyme/Lumizyme) — recombinant human acid alpha-glucosidase administered IV every 2 weeks; significantly improves survival and motor function in classic infantile Pompe if started early
- Avalglucosidase alfa (Nexviazyme) — newer, more effective ERT with enhanced M6P receptor binding; approved 2021
- Cipaglucosidase alfa + miglustat (Pombiliti + Opfolda): ERT + enzyme stabilizer combination; approved 2023
- Cardiac monitoring and management of cardiomyopathy
- Respiratory support, physiotherapy, nutritional support
- Newborn screening: now included in many countries' NBS panels — early treatment before symptoms dramatically improves outcomes
🔭 Recent Advances — Exam Q&A
Three therapies are currently approved, representing different molecular strategies:
| Drug | Mechanism | Year Approved | Route |
|---|---|---|---|
| Nusinersen (Spinraza) | Antisense oligonucleotide that modifies SMN2 pre-mRNA splicing, forcing inclusion of exon 7 → more full-length SMN protein | FDA 2016 | Intrathecal injection |
| Onasemnogene abeparvovec (Zolgensma) | AAV9 gene therapy carrying functional SMN1 transgene; one-time treatment; durable effect | FDA 2019 | Single IV infusion |
| Risdiplam (Evrysdi) | Small molecule SMN2 splicing modifier (similar to nusinersen but CNS and peripheral penetration); oral bioavailability | FDA 2020 | Daily oral syrup |
The FIREFISH (risdiplam) and ENDEAR (nusinersen) trials showed significant improvement in motor milestones and survival. Presymptomatic treatment (identified via newborn screening) yields the best outcomes.
SMA is now included in newborn screening (NBS) panels in many countries (USA since 2018). NBS identifies SMN1 deletion via dried blood spot PCR before symptom onset.
Importance: Motor neurons in SMA die progressively from birth. By the time clinical symptoms appear, a significant percentage of motor neurons are already lost. Pre-symptomatic treatment with DMTs (especially Zolgensma) prevents neuronal loss and can allow infants to achieve near-normal motor milestones — essentially changing the natural history of SMA Type I from a fatal disease to a manageable condition.
Clinical trials (SPR1NT for Zolgensma; NURTURE for nusinersen) showed that pre-symptomatic infants treated with DMTs achieved sitting, standing, and even walking — milestones previously impossible in SMA Type I.
NGS-based approaches (whole exome sequencing / whole genome sequencing) are increasingly used when targeted testing fails to reveal a diagnosis. Key roles:
- Identifies mutations in rare congenital myopathy genes (RYR1, NEB, ACTA1, TTN, DNM2, etc.) where single-gene testing is impractical
- Detects novel or atypical presentations of known conditions
- A 2022 JAMA Neurology consensus review recommended genomic sequencing (WES or WGS) early in the diagnostic workup — particularly for infants with hypotonia where traditional investigations are unrevealing
- Rapid WGS (rWGS) turnaround of 24–72 hours is now possible in some centers for critically ill neonates
- Avalglucosidase alfa (Nexviazyme, 2021): Next-generation ERT with higher M6P-receptor affinity (approximately 15× higher uptake in muscle than standard alglucosidase alfa); superior outcomes in both infantile and late-onset Pompe
- Cipaglucosidase alfa + miglustat (Pombiliti + Opfolda, 2023): ERT stabilized by a pharmacological chaperone (miglustat), protecting the enzyme from degradation in lysosomes
- Gene therapy: Multiple ongoing phase I/II trials targeting GAA gene replacement via AAV vectors
- NBS: Many countries now screen for Pompe on dried blood spot (acid alpha-glucosidase activity assay + confirmatory GAA gene sequencing)
CHOP-INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) is a validated motor function assessment scale specifically designed for infants with SMA Type I and other neuromuscular disorders.
- Consists of 16 items assessing voluntary motor responses across different body segments
- Scored 0–64 (higher = better motor function)
- Used in clinical trials to measure treatment efficacy of nusinersen and risdiplam
- Infants with SMA I typically score <20 without treatment
- Significant improvements in CHOP-INTEND scores after DMT treatment in clinical trials
⚡ Key Points — Quick Revision
One-Liners for Exam
- Floppy infant: Reduced resistance to passive movement + poor postural control against gravity
- Central hypotonia: 60–80% of all cases; most common cause = HIE
- Key differentiator: Alert + profound weakness + areflexia = Peripheral; Encephalopathic + normal/brisk DTRs = Central
- Tongue fasciculations: Pathognomonic of anterior horn cell disease (SMA)
- Bell-shaped chest + paradoxical breathing: Intercostal muscle weakness (SMA) — intercostals weak, diaphragm spared
- SMA Type I (Werdnig-Hoffmann): Onset <6 months, never sits, SMN1 deletion (5q13), AR inheritance
- SMA Rx: Nusinersen (intrathecal), Onasemnogene abeparvovec (IV gene therapy), Risdiplam (oral)
- Prader-Willi: Hypotonia + hypogonadism in infancy → hyperphagia + obesity later; del 15q11-13 (paternal)
- Down syndrome: Trisomy 21 → central hypotonia, upslanting fissures, simian crease, CHD (40–50%)
- Pompe disease: Floppy infant + cardiomegaly + macroglossia = Acid maltase deficiency; Rx: ERT (alglucosidase)
- Infant botulism: Constipation FIRST → descending paralysis; source = honey/soil; Rx: BabyBIG (BIG-IV)
- Neonatal MG: Maternal AChR antibodies → transient (resolves 2–8 wks); Rx: neostigmine
- CK in SMA: Normal or mildly elevated (NOT a myopathy marker)
- Gold standard SMA diagnosis: SMN1 gene deletion (MLPA/PCR) — EMG/muscle biopsy not needed if typical
- Gold standard investigation for central hypotonia: MRI brain + karyotype/chromosomal microarray
- Benign congenital hypotonia: Diagnosis of exclusion; normal investigations; improves with time
- Presymptomatic SMA treatment: Best outcomes; NBS programs now screen for SMA
🚨 Common Exam Traps
- A soft murmur in a large VSD paradox doesn't apply here — in SMA, preserved cognition in a profoundly weak infant should always raise suspicion of peripheral cause
- Do NOT give aminoglycosides in botulism — they worsen NMJ blockade
- Congenital myotonic dystrophy is almost always from the MOTHER (paternal CTD does not cause congenital form)
- Neonatal MG resolves spontaneously — do NOT start immunosuppression
- Muscle biopsy is not required for SMA if SMN1 deletion is confirmed genetically
- Prader-Willi in infancy mimics SMA but has no tongue fasciculations, has dysmorphic features and hypogonadism
💡 Localization Summary
| Level | Key Disease | Hallmark Feature |
|---|---|---|
| Brain/CNS | HIE, Down, PWS | Encephalopathy, dysmorphism, seizures, brisk/normal DTRs |
| Anterior Horn Cell | SMA I | Alert, tongue fasciculations, areflexia, bell chest |
| Peripheral Nerve | CMT, hypomyelinating neuropathy | Areflexia, slow NCV, ± sensory loss |
| NMJ | Botulism, neonatal MG | Fatigability, descending paralysis (botulism), maternal MG history |
| Muscle | Congenital myopathy, Pompe | Facial weakness, high CK (Pompe: cardiomegaly) |